Chief Medical Officer
Novamind, Inc.
Provo, Utah
Reid Robison, MD MBA, is a board-certified psychiatrist, psychedelic researcher and Chief Medical Officer at Novamind. Reid has led over 200 clinical trials in neuropsychiatry and previously co-directed the molecular genetics laboratory at the University of Utah Department of Psychiatry. He was one of the first clinicians to use ketamine off-label for depression in Utah and obtained his first grant to study ketamine in 2011. Reid led the Utah site for the pivotal IV ketamine study for treatment-resistant depression by Janssen, leading up to the company’s recent FDA-approval of Spravato (esketamine) via breakthrough therapy designation in 2019. He later served as coordinating investigator for the MAPS MDMA-assisted Psychotherapy study of Eating Disorders. He currently leads a number of psychedelic studies in Utah as Principal Investigator, including clinical trials assessing psilocybin for depression and LSD for anxiety. To date, Reid has guided thousands of ketamine therapy journeys and Spravato dosing sessions. He has co-developed specific forms of ketamine-assisted psychotherapy, and supervises and trains psychedelic-assisted psychotherapy practitioners. Reid also serves as Medical Director of Center for Change, a top eating disorder treatment facility in Utah. He is a board member of the Psychedelic Medicine Association and Psychedelic institute and participates on the advisory boards of multiple organizations in the psychedelic space, including Enthea, Apex Innovative Sciences, and Mind Medicine Australia. Reid is adjunct faculty at the University of Utah and Brigham Young University, founder of the Polizzi Free Clinic, and provides medical and therapy support at plant medicine retreats abroad.
Disclosure information not submitted.
Thursday, October 13, 2022
11:00 AM – 11:30 AM ET